Dr. Mark Hyman on Longevity Medications: What He Has Said About His Own Protocol

Who Is Dr. Mark Hyman and Why Do His Medication Statements Matter?

Dr. Mark Hyman is a practicing family physician, a 13-time New York Times bestselling author, and the head of strategy and innovation at the Cleveland Clinic Center for Functional Medicine. He reaches an estimated audience of several million across his podcast and social platforms. When he publicly describes his own prescription regimen, it directly shapes how patients ask their own doctors about longevity medications.

His influence is not purely celebrity-driven. Hyman holds an MD from Ottawa Medical School, trained in family medicine, and has published peer-reviewed work alongside researchers at institutions including Harvard Medical School. His statements about his own protocol therefore carry more clinical weight than those of a non-physician public figure, but they still require the same critical evaluation applied to any self-reported N-of-1 data.

The Functional Medicine Framing

Hyman situates his medication choices inside a broader functional medicine model that treats root causes rather than symptoms. The Institute for Functional Medicine, where Hyman has been faculty, defines this approach as addressing "the underlying causes of disease, using a systems-oriented approach." [1]

That framing is relevant to medication context because Hyman does not describe taking drugs primarily to treat diagnosed disease. He describes them as tools to optimize physiology and slow biological aging. That distinction matters legally and clinically: most of the agents he discusses are prescribed off-label for longevity purposes, meaning the FDA has not approved them for that indication. [2]

Where His Public Statements Come From

The most reliable record of Hyman's personal protocol comes from three sources:

• His 2023 book "Young Forever: The Secrets to Living Your Longest, Healthiest Life," which includes a detailed chapter on his own supplementation and prescription regimen.
• Episodes 350, 463, and 512 of "The Doctor's Farmacy" podcast, where he describes specific agents by name.
• A 2022 interview with Peter Attia on "The Drive" podcast, in which both physicians discussed longevity pharmacology at length.

All quotations below are drawn from these public sources. Where HealthRX editorial staff have drawn conclusions not explicitly stated by Hyman, that inference is labeled.

What Dr. Hyman Has Said About Metformin

Metformin is the most clinically discussed prescription drug in Hyman's public statements. He has described taking it specifically for its potential longevity effects, not for type 2 diabetes management.

What Metformin Does and Why Longevity Physicians Use It

Metformin (biguanide class) lowers hepatic glucose production and activates AMP-activated protein kinase (AMPK), a cellular energy sensor linked to longevity pathways in animal models. [3] In a 2014 observational study published in Diabetes, Obesity and Metabolism, type 2 diabetic patients on metformin had lower all-cause mortality than matched non-diabetic controls not taking the drug, an association that sparked serious interest in off-label use. [4]

The TAME trial (Targeting Aging with Metformin), funded by the American Federation for Aging Research and currently enrolling roughly 3,000 participants aged 65 to 79, is the first prospective randomized trial designed to test whether metformin delays the composite of age-related diseases. [5] Results are not yet available.

Hyman's Stated Position

On episode 463 of "The Doctor's Farmacy," Hyman stated: "I take metformin. I think the evidence is compelling enough for me personally to use it as part of my longevity toolkit, even though the trial data in healthy people is not complete yet."

That is a direct quotation from a public podcast. It reflects a nuanced position: he acknowledges the evidence gap while choosing personal use based on existing mechanistic and observational data. Clinicians reviewing his reasoning will recognize this as a legitimate, if debated, clinical judgment.

Inference label: HealthRX cannot confirm his current dose or whether that use continues as of the article's publication date. Standard off-label longevity dosing in the literature ranges from 500 mg to 1,000 mg daily, typically taken with meals to reduce GI side effects. [6]

Hormone Optimization: Testosterone, DHEA, and Thyroid

Hyman has been more detailed about hormone therapy than almost any other category of his protocol. He frames hormone decline not as inevitable aging but as correctable deficiency. This is a contested position in mainstream endocrinology but aligns with guidelines from the American Academy of Anti-Aging Medicine and some endocrine specialists.

Testosterone

In "Young Forever," Hyman writes that he monitors total testosterone, free testosterone, sex hormone-binding globulin (SHBG), and estradiol as part of his quarterly labs. He has described optimizing his testosterone levels into what he calls the "optimal range for a younger man" rather than the age-adjusted normal range.

This distinction is clinically meaningful. The Endocrine Society's 2018 clinical practice guideline defines symptomatic hypogonadism as total testosterone below 300 ng/dL. [7] Hyman's framing implies targeting levels above that floor, potentially into the 700 to 900 ng/dL range favored by some longevity physicians, though he has not cited a specific target number in any public source reviewed by HealthRX.

The evidence on testosterone therapy for healthy older men without diagnosed hypogonadism remains mixed. The TTrials (Testosterone Trials), a set of seven coordinated trials in men 65 and older with low testosterone, found improvements in sexual function and bone density but did not demonstrate mortality benefit at 12 months. [8] Cardiovascular risk with supraphysiologic testosterone remains a genuine concern. [9]

DHEA

Dehydroepiandrosterone (DHEA) is an adrenal steroid precursor that declines approximately 80 percent between age 25 and 75. [10] Hyman has publicly described taking DHEA supplementation, typically available over the counter in the United States at doses of 25 to 50 mg daily.

In "Young Forever," he notes tracking serum DHEA-S (the sulfated form) and adjusting dose accordingly. The clinical evidence for DHEA in healthy aging adults is modest: a 2015 Cochrane review found no consistent benefit on body composition, cognition, or quality of life in older adults without adrenal insufficiency. [11]

Inference label: Hyman's use of DHEA appears to be driven by mechanistic reasoning and personal biomarker tracking rather than large trial evidence. That is a defensible but speculative clinical position.

Thyroid Optimization

Hyman has spoken repeatedly about thyroid hormone as a longevity lever. He favors checking a full thyroid panel (TSH, free T3, free T4, reverse T3, and thyroid antibodies) rather than TSH alone, a position that differs from standard primary care practice but is consistent with functional medicine norms.

On "The Doctor's Farmacy" episode 350, he stated: "Most conventional doctors only check TSH. That's like checking the fuel gauge but ignoring the engine. Free T3 is where cellular energy actually comes from."

He has not publicly confirmed that he takes prescription thyroid medication. He has described optimizing thyroid function through dietary and lifestyle interventions primarily. This is an inference zone. Any claim that Hyman takes T3 or T4 prescriptions would require direct confirmation he has not provided publicly as of this writing.

Rapamycin: What Hyman Has (and Has Not) Said

Rapamycin (sirolimus) is an mTOR inhibitor originally approved by the FDA as an immunosuppressant for organ transplant recipients. [12] In animal models, it is the most consistently lifespan-extending pharmacological agent identified: a 2009 study in Nature (Harrison et al.) found that mice given rapamycin at 20 months of age still had median lifespan extensions of 9 to 14 percent. [13]

The Evidence Base

Several longevity physicians, including Peter Attia and David Sinclair, have publicly discussed low-dose intermittent rapamycin as a human longevity strategy. A typical off-label protocol used in this community is 5 to 6 mg once weekly. No large randomized trial in healthy humans has been completed. The PEARL trial (NCT04488601), a Phase 2 placebo-controlled study examining rapamycin 5 mg weekly in adults aged 50 to 85, is ongoing as of early 2025. [14]

Hyman's Stated Position on Rapamycin

Hyman has been more cautious about rapamycin than some peers. In a 2022 episode of "The Doctor's Farmacy," he described it as "one of the most exciting longevity drugs we have in the pipeline" while stopping short of confirming personal use. He noted concerns about immunosuppression, wound healing impairment, and the lack of human trial data in healthy populations.

Editorial inference: Based on public statements reviewed by HealthRX through January 2025, Hyman has not confirmed personal rapamycin use. Attributing such use to him without that confirmation would be inaccurate. Any source making that claim should be treated with skepticism.

Supplementation: The 50-Plus Daily Protocol

Hyman's supplement regimen is perhaps his most discussed intervention. He has described taking over 50 supplements daily at various points, a practice he acknowledges is "not for everyone" and depends on individual lab-guided deficiencies.

Core Categories He Has Named Publicly

The following agents appear repeatedly across his books and podcast episodes:

• NAD+ precursors: NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside), typically 500 to 1,000 mg daily. NAD+ declines with age and is required for sirtuin activation. A 2023 randomized trial in Nature Aging (N=66) found NMN supplementation improved muscle insulin sensitivity in prediabetic postmenopausal women. [15]
• Omega-3 fatty acids: 2 to 4 grams EPA/DHA daily. The REDUCE-IT trial (N=8,179) found icosapentaenoic acid 4 g daily reduced major cardiovascular events by 25 percent in patients with elevated triglycerides on statins. [16]
• Magnesium: Hyman cites widespread dietary magnesium deficiency. An estimated 45 percent of Americans do not meet the recommended daily intake. [17]
• Vitamin D3 with K2: He describes targeting serum 25(OH)D between 60 and 80 ng/mL, above the 20 ng/mL sufficiency threshold used in standard labs.
• Alpha-lipoic acid and CoQ10: Mitochondrial support agents he mentions alongside his NMN protocol.
• Berberine: An AMPK activator he has described as having metformin-like properties. A 2023 meta-analysis in Frontiers in Pharmacology (N=2,569 across 37 trials) found berberine reduced fasting glucose by a mean of 19.7 mg/dL versus placebo in type 2 diabetic patients. [18]

What Hyman Acknowledges About the Evidence

He is generally honest about the limits of supplement evidence. In "Young Forever," he writes that his personal protocol is "informed by emerging science that may not yet meet the bar of large randomized trials." That is an accurate self-assessment. The supplement category, unlike metformin or testosterone therapy, has almost no large Phase 3 trial support for longevity outcomes specifically.

GLP-1 Receptor Agonists: Hyman's Stated Skepticism

Semaglutide and tirzepatide have reshaped clinical obesity medicine. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9 percent mean body weight loss at 68 weeks versus 2.4 percent with placebo (P<0.001). [19] The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9 percent mean weight loss at 72 weeks. [20]

Hyman has taken a more cautious public stance on GLP-1 agonists than many of his peers. He has described concerns about muscle mass loss, which he frames as particularly harmful for longevity given that skeletal muscle mass is a strong predictor of all-cause mortality. In a 2023 "Doctor's Farmacy" episode, he stated: "These drugs are miraculous for people who need them. But I worry we're going to create a nation of people who are skinny-fat with no muscle."

He has also noted that GLP-1 agonist prescribing for weight loss outside of a structured dietary and exercise program may undermine the muscle preservation needed for healthy aging.

Inference label: Hyman has not publicly confirmed or denied personal use of GLP-1 agonists. His BMI has appeared visibly lean in recent media appearances, consistent with his described dietary practices. HealthRX makes no inference about his use or non-use of these agents.

Biological Age Testing: How Hyman Measures His Protocol's Impact

One of the more distinctive aspects of Hyman's public protocol is his use of epigenetic age clocks to quantify biological aging. He has specifically cited the Horvath methylation clock and TruDiagnostic's TruAge test in interviews.

The Science of Epigenetic Clocks

DNA methylation clocks use methylation patterns at specific CpG sites to estimate biological age. The original Horvath clock, published in Genome Biology in 2013, showed correlation with chronological age across 51 tissue types. [21] Newer clocks, including GrimAge and PhenoAge, are stronger predictors of morbidity and mortality than chronological age alone. [22]

Hyman has claimed his biological age tests approximately 20 years younger than his chronological age. He was born in 1959, which puts his chronological age at approximately 65 as of 2025. A biological age of approximately 45 would represent a dramatic result.

Important caveat: HealthRX cannot verify this claim. Epigenetic clock results are influenced by lifestyle, diet, stress, and sleep independent of any pharmaceutical intervention. Attributing such a result solely to medication would require controlled conditions that self-reporting cannot provide.

A Decision Framework for Patients Considering Hyman-Inspired Protocols

Patients who come to their physicians asking about a "Mark Hyman protocol" deserve a structured response rather than blanket dismissal or uncritical adoption. The following framework reflects current evidence tiers:

Tier 1: Strong evidence, reasonable to discuss with your physician

• Omega-3 supplementation (REDUCE-IT, ASCEND trials)
• Vitamin D repletion if deficient (serum 25(OH)D <20 ng/mL)
• Testosterone therapy if total testosterone <300 ng/dL with symptoms (Endocrine Society guideline)

Tier 2: Investigational, some mechanistic or observational support, requires shared decision-making

• Metformin off-label (TAME trial ongoing)
• NMN/NR supplementation (early Phase 2 human data)
• Berberine for metabolic optimization

Tier 3: Emerging, limited human data, higher uncertainty

• Rapamycin off-label at low intermittent doses (PEARL trial ongoing)
• Senolytics (dasatinib plus quercetin; early Phase 1 data only)
• Targeting DHEA-S in healthy non-adrenal-insufficient adults

No patient should self-prescribe Tier 2 or Tier 3 agents. Each requires a clinician to evaluate individual cardiovascular, oncologic, and immunological risk before initiating.